PRINTER'S NO. 2394
THE GENERAL ASSEMBLY OF PENNSYLVANIA
HOUSE RESOLUTION
No.
459
Session of
2019
INTRODUCED BY STRUZZI, JOZWIAK, PASHINSKI, PICKETT AND
SCHLOSSBERG, SEPTEMBER 3, 2019
REFERRED TO COMMITTEE ON HEALTH, SEPTEMBER 3, 2019
A RESOLUTION
Urging the United States Food and Drug Administration to
promptly consider guidelines and protocols for the approval
of cannabidiol as a product which is legally available for
resale.
WHEREAS, The United States is seeing a change in the use of
marijuana for medical purposes; and
WHEREAS, Thirty-three states and the District of Columbia
have recognized that marijuana may have medical purposes; and
WHEREAS, This Commonwealth is one of the states which has
legalized the use of medical marijuana for limited purposes,
including serious medical conditions; and
WHEREAS, Under Federal law, the 2018 Farm Bill has created
additional questions with respect to the definition of marihuana
in Schedule I of the Controlled Substances Act; and
WHEREAS, Cannabidiol (CBD) is a product which can be derived
from a variety of marijuana plants, including, industrial hemp;
and
WHEREAS, The Federal Government has removed hemp and all
parts of the plant from the definition of marihuana in Schedule
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
I of the Controlled Substances Act; and
WHEREAS, The United States Food and Drug Administration (FDA)
has previously approved epidiolex as a medicine which contains
CBD; and
WHEREAS, It is unclear whether or not the FDA regulates
commercially available CBD; and
WHEREAS, It is in the interest of public safety to have a
streamlined and consistent oversight system for CBD and CBD
products; therefore be it
RESOLVED, That the House of Representatives of the
Commonwealth of Pennsylvania urge the United States Food and
Drug Administration to promptly consider guidelines and
protocols for approval of cannabidiol as a product which is
legally available for resale; and be it further
RESOLVED, That a copy of this resolution be transmitted to
the headquarters of the United States Food and Drug
Administration at 10903 New Hampshire Avenue, Silver Spring,
Maryland 20993.
20190HR0459PN2394 - 2 -
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18